Research Reports on Biotech Equities -- Celgene, Sarepta Therapeutics, Threshold Pharma, and MannKind

Oct 06, 2016, 05:15 ET from Chelmsford Park SA

NEW YORK, October 6, 2016 /PRNewswire/ --

Today, has its attention directed to the Biotechnology arena which entered about a month ago in the triple leveraged ETF at about $38 a share, and exited last week on a stop-loss order of $50 a share, as per an article on Seeking Alpha. We have issued for premarket this morning the following reports on: Celgene Corp. (NASDAQ: CELG), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), and MannKind Corp. (NASDAQ: MNKD) to see how they have fared over the last few trading sessions. Learn more about these stocks by accessing their free research reports at:


Summit, New Jersey headquartered Celgene Corp.'s stock finished Wednesday's session 0.59% higher at $105.29 with a total trading volume of 2.60 million shares. The Company's shares have advanced 0.84% in the previous three months. The stock is trading 0.17% below its 200-day moving average. Additionally, shares of Celgene, which discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide, have a Relative Strength Index (RSI) of 44.05.

On October 4th, 2016, Celgene announced that the data from a randomized, double-blind, multicenter, exploratory phase Ib study evaluating the effects of oral GED-0301 (mongersen) on both endoscopic and clinical outcomes in patients with active Crohn's disease were accepted as a late breaking abstract at the United European Gastroenterology Week. Free research report on CELG is available at:

Sarepta Therapeutics

On Wednesday, shares in Cambridge, Massachusetts headquartered Sarepta Therapeutics Inc. recorded a trading volume of 1.63 million shares. The stock ended the session 1.42% higher at $62.35. The Company's shares have surged 124.36% in the last one month, 198.04% in the previous three months, and 61.61% on an YTD basis. The stock is trading 82.14% above its 50-day moving average and 168.26% above its 200-day moving average. Moreover, shares of Sarepta Therapeutics, which focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases, have an RSI of 77.02.

On September 28th, 2016, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $83 a share to $108 a share.

On October 4th, 2016, Sarepta Therapeutics and Summit Therapeutics PLC announced that they have entered into an exclusive license and collaboration agreement granting Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States, to Summit's utrophin modulator pipeline, including its lead clinical candidate, ezutromid, for the treatment of Duchenne muscular dystrophy. As part of the agreement, Sarepta also obtains an option to license Latin American rights to Summit's utrophin modulator pipeline. The complimentary research report on SRPT can be downloaded at:

Threshold Pharma

Shares in South San Francisco, California headquartered Threshold Pharmaceuticals Inc. closed the day 6.47% higher at $0.59. The stock recorded a trading volume of 1.41 million shares. The Company's shares have gained 22.69% on an YTD basis. The stock is trading 8.55% above its 200-day moving average. Additionally, shares of Threshold Pharmaceuticals, which discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the US, have an RSI of 29.92.

On September 29th, 2016, Threshold Pharmaceuticals announced interim data from its two Phase 2 proof-of-concept clinical trials of tarloxotinib and outlined its plans to focus company resources on the more clinically-advanced evofosfamide program as well as an earlier-stage anticancer candidate, TH-3424. The company stated that in the first stage of the squamous cell carcinoma of the skin arm of the trial, a confirmed partial response was observed in 1 of 7 patients. According to the study design, the response rate was sufficient to expand the trial to evaluate additional patients. Visit us today and access our complete research report on THLD at:


At the close, shares in Valencia, California headquartered MannKind Corp. ended the day at $0.63, climbing 1.78%. The stock recorded a trading volume of 2.15 million shares. The Company's shares are trading below their 50-day moving average by 23.00%. Furthermore, shares of MannKind, which focuses on the discovery, development, and commercialization of therapeutic products for diabetes patients in the US, have an RSI of 37.19.

As per notes filed with the SEC on September 22nd, 2016, MannKind received a letter from The NASDAQ Stock Market on September 14th, 2016, indicating that for 30 consecutive business days the company's common stock had not maintained a minimum closing bid price of at least $1.00 per share as required by NASDAQ Listing Rules. The company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement under the NASDAQ Listing Rules. Get free access to your research report on MNKD at:


Stock Callers:

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA